Mai O. Kadry is a distinguished researcher at the National Research Centre in Giza, Egypt, recognized for her multidisciplinary contributions across metabolomics, molecular oncology, nanomedicine, toxicology, and women’s health research. Her scientific portfolio reflects a sustained commitment to unraveling the biochemical and molecular mechanisms underpinning complex diseases, with a particular focus on metabolic disorders, cancer progression, reproductive toxicology, and innovative therapeutic strategies. Through a substantial body of peer-reviewed publications, she has advanced understanding of how metabolic signatures, genomic interactions, and molecular signaling pathways can be leveraged to improve disease diagnosis, treatment response, and therapeutic safety. Her work frequently integrates serum metabolomics, network pharmacology, lipidomics, nanostructure-based drug delivery, and experimental validation models, enabling a comprehensive systems-level view of disease processes. She has collaborated extensively with national and international scientists, contributing to multidisciplinary studies on phytotherapeutics for endocrine disorders, nanoscale interventions to mitigate chemotherapeutic toxicity, and molecular crosstalk driving drug resistance in cancer cells. Her authorship and citation footprint reflect broad scholarly engagement, while her active participation in multi-institutional teams has supported knowledge exchange and capacity building within the biomedical research community. Kadry’s investigations into natural product therapeutics, oxidative brain injury mechanisms, autophagy regulation, and emerging RNA-based biomarkers contribute to public health and precision medicine, offering insights with potential translational relevance to women’s health, oncology, toxicology, and environmental exposure science. Collectively, her work demonstrates a strong commitment to scientific innovation, interdisciplinary integration, and the societal importance of developing safer, more effective therapeutic approaches that align with global health priorities. She has 462 citations from 50 documents with an h-index of 12.
Profiles: Scopus | ORCID
Publications
1. Kadry, M., Author, A. A., Author, B. B., … (2025). Exploring the therapeutic potential of marjoram (Origanum majorana L.) in polycystic ovary syndrome: Insights from serum metabolomics, network pharmacology and experimental validation.
2. Kadry, M., & Author, A. A. (2025). Novel insights into SNORD-78 and miR-122-5P: The predicted diagnostic indexes of lung cancer—Drug-loaded liposome formulations competing methylcholanthrene-induced lung cancer.
3. Kadry, M., Author, A. A., Author, B. B., Author, C. C., & Author, D. D. (2025). Oxidative brain injury ascending from DMBA: Metabolomics and BRAF3/FKBR/A2m molecular signaling crosstalk.
4. Kadry, M., Author, A. A., Author, B. B., … (2025). Metabolomics integrated genomics approach: Understanding multidrug resistance phenotype in MCF-7 breast cancer cells exposed to doxorubicin and ABCA1/EGFR/PI3K/PTEN crosstalk.
5. Kadry, M., Author, A. A., & Author, B. B. (2025). Titanium nanostructure mitigating doxorubicin-induced testicular toxicity in rats via regulating major autophagy signaling pathways.